ClinicalTrials.gg
RecruitingNCT06666283Updated Sep 11, 2025

A Study to Evaluate the Safety, Tolerability, PK and PD of AP303 in DKD Patients

A Phase 1 interventional study of AP303 150μg and Placebo 150μg in Diabetic Kidney Disease, sponsored by Alebund Pharmaceuticals. Recruiting at 1 site in China. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2025-09-11.

Sponsored by Alebund Pharmaceuticals · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year 1 month ago, but the record still lists the study as recruiting.
  • Started Feb 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
30 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 75 studies in Diabetic Nephropathies with a site in China — 22 open to participants now, 30 under way, none of them phase 3. Diabetic Nephropathies · China.

Planned enrollment
48th of 52
18 · median 122
Started
2025
with 6 others
Phase 1
8 of 75
2 open now
Primary completion
2025-09
later than 8 of 29 live
Registered
59th of 75
by date
Lead sponsor
1 of 75
Alebund Pharmaceuticals

Among the 75 studies in Diabetic Nephropathies with a site in China, this one is the 48th largest by planned enrollment of the 52 interventional ones that give a count, is one of 7 that started in 2025, is one of 8 in phase 1, reaches primary completion later than 8 of the 29 other live ones, and was the 59th registered.

Diabetic Nephropathies

544 studies on the registry are indexed under Diabetic Nephropathies; 110 are open to participants now.

Browse Diabetic Nephropathies studies →

Open to participants now

22 of the 75 studies in Diabetic Nephropathies with a site in China are open now. Recruiting first, the newest first:

16 more — sign in →

All 22 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 50 Diabetic Nephropathies studies recruiting now, 23 (46%) set no upper age limit and 16 (32%) stop at 75 or younger; 5 take children under 18; 8 take healthy volunteers.

This study: 30 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in Diabetic Nephropathies with a site in China, or all of them as a file.
02

Study summary

The study will be a single center, double-blind, randomized, placebo-controlled study to evaluate the safety, tolerability, PK and PD of AP303 following 2-week oral administration to Diabetic Kidney Disease patients.

Read the detailed description

Eligible patients will be enrolled into one of the two dose cohorts, each cohort will include 9 participants randomized to AP303 and placebo at a 2:1 ratio (6 on AP303 and 3 on placebo).

03

Conditions studied

  • Diabetic Kidney Disease
04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female participants, ≥30 years of age at the time of signing the form.
  2. (body mass index) 18-30 kg/m².
  3. Patient has a clinical diagnosis of Type 2 Diabetes Mellitus and is taking at least one type of hypoglycemic drugs, before screening visits, the doses of hypoglycemic drugs, including insulin, need to be stable for at least two weeks..
  4. Patient must be on a stable dose of angiotensin converting anzyme inhibitior (ACEI) or Angiotensin II receptor blockers (ARB) for at least 4 weeks prior to screening.
  5. ≥6.5% but ≤10.5% at the screening visit.
  6. Estimated ≥30 mL/min/1.73m² but \< 60 mL/min/1.73m² at the screening visit.
  7. Urinary albumin to creatinine ratio ≥ 30 mg/g at the screening visit.

Exclusion criteria

Exclusion Criteria:

  1. Chronic kidney disease other than type 2 diabetic kidney disease.
  2. Patient receiving immunotherapy or other (such as calcineurin inhibitors ciclosporin, cyclophosphamide, or mycophenolate mofetil) in the past 3 months before screening.
  3. Recently having acute kidney injury or received renal surgery within the last 6 months before screening visit, or have received renal transplantation.
  4. Congestive heart failure classified (NYHA) class II to IV within the last 3 months before the screening visit.
  5. Peripheral edema above the ankle level at the screening or randomization visit.
  6. Confirmed (based on the average of 2 separate resting blood pressure measurements in a sitting position, after at least 5 minutes rest) systolic BP greater than 160 or less than 90 mmHg, and diastolic BP greater than 100 or less than 50 mmHg at screening.
  7. Myocardial infarction, acute coronary syndrome, stroke or , cardiovascular surgery within 6 months prior to the screening visit.
  8. Abnormalities of parameters and abnormal shape of ECG wave on screening ECG: e.g.

    • (QTcF > 450 ms for male and QTcF > 470 ms for female) based on the average interval on triplicate ECGs obtained after 5 minute's rest in a supine position
    • Notable resting bradycardia (mean HR \< 40 bpm)
    • Notable resting tachycardia (mean HR > 100 bpm)
    • ECG with QRS and/or T wave judged to be unfavorable for a consistently accurate QT measurement (e.g., neuromuscular artifact that cannot be readily eliminated, indistinct QRS onset, low amplitude T wave, merged T- and U-waves, prominent U waves)
    • Any other significant abnormality
  9. Implantation of cardiac pacemaker or arrhythmia, e.g. atrial fibrillation, atrial flutter, right or left bundle branch block, Wolf-Parkinson-White Syndrome.
  10. Current or previous treatment with a thiazolidinedione (e.g., medications containing pioglitazone or rosiglitazone, like Actos, Avandia, ActoplusMet, Avandamet, Avandaryl), PPARa agonist (like fenofibrate) or any dual/multiple PPARa/g agonist (e.g., Chiglitazar Sodium) in the 3 months preceding screening visit.
  11. Previous treatment with CYP2C8 inducer or strong/moderate inhibitor (refer to the list in Appendix 4) in the 1 month preceding screening visit.
  12. Chronic therapy with non-steroidal anti-inflammatory drugs (NSAIDs) (except prophylactic stable low dose aspirin, defined as its dose not higher than 100 mg daily; paracetamol/acetaminophen was allowed) in the last month before screening.
  13. or AST >1.5 × , or laboratory tests revealed other clinically significant abnormalities in liver function at screening.
  14. Creatine phosphokinase (CPK) elevated > 3 x ULN at screening visit or history of drug-induced myopathy.
  15. History of within 5 years before screening (exceptions: squamous and basal cell carcinomas of the skin and carcinoma of the cervix in situ, or a malignancy that in the opinion of the investigator, with concurrence with the sponsor's medical monitor, is considered cured with minimal risk of recurrence).
  16. Participants who have had significant acute infection, e.g., COVID-19, influenza, local infection, acute gastrointestinal symptoms or any other clinically significant illness within two weeks before study drug administration.
  17. Positive test at screening of any of the following: (HBsAg), (HCVAb), (HIV Ab) or syphilis AB.
  18. Dosed with a small-molecule drug within 3 months, or biologic investigational drug within 3 months or 5 half-lives (whichever is the longer) prior to first dose of this study.
  19. History of drug and/or alcohol abuse or addiction. History (within 3 months of screening) of alcohol consumption exceeding 3 and 2 standard drinks per day on average (1 standard drink = 10 grams of alcohol) for male and female, respectively.
  20. Within 2 weeks prior to admission, use of >5 cigarettes or equivalent nicotine-containing product per day.
  21. Medical or social conditions that would potentially interfere with the participant's ability to comply with the study visit schedule or the study assessments.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    AP303

    Drug: AP303 150μg

  • Placebo comparator
    Placebo

    Drug: Placebo 150μg

Interventions

  • DrugAP303Studies of AP303AP303 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    AP303 Tablet 150μg QD

  • DrugPlacebo 150μg

    Placebo Tablet 150μg QD

06

What researchers measure

Primary outcomes

  1. Cmax

    Maximum observed plasma concentration

    Time frame: Day 1, Day 14

  2. Tmax

    Time to maximum observed plasma concentration

    Time frame: Day 1, Day 14

  3. AUC0-24h

    Area under the plasma concentration versus time curve up to 24 hours

    Time frame: Day 1

  4. AUC0-last

    Area under the plasma concentration versus time curve up to the last measurable concentration

    Time frame: Day 1

  5. AUC0-inf

    Area under the plasma concentration versus time curve extrapolated to infinity

    Time frame: Day 1

  6. AUC0-t

    Area under the plasma concentration-time curve for a dosing interval

    Time frame: Day 14

  7. t1/2

    Apparent terminal half-life, computed as ln(2)/λz

    Time frame: Day 1, Day 14

  8. CL/F

    Apparent oral clearance calculated from Dose/ AUC0-inf

    Time frame: Day 1

  9. V/F

    Apparent volume of distribution of oral drug

    Time frame: Day 1, Day 14

  10. Cav

    Average plasma concentration

    Time frame: Day 14

  11. Ctrough

    Trough plasma concentration

    Time frame: Day 3-14

  12. Rac

    Ratio of accumulation

    Time frame: Day 3-14

  13. Incidence and severity of adverse events

    Incidence and severity of adverse events

    Time frame: Day 1-28

  14. Incidence of laboratory abnormalities, based on hematology, clinical chemistry, coagulation and urinalysis test results

    Incidence of laboratory abnormalities, based on hematology, clinical chemistry, coagulation and urinalysis test results

    Time frame: Day 1-28

  15. Effect of AP303 on ECG parameters

    Change of Heart rate in beats/min

    Time frame: Day 1-28

  16. Effect of AP303 on ECG parameters

    change of QT in ms

    Time frame: Day 1-28

  17. Effect of AP303 on ECG parameters

    Change of PR in ms

    Time frame: Day 1-28

  18. Effect of AP303 on ECG parameters

    Change of QRS in ms

    Time frame: Day 1-28

  19. Effect of AP303 on ECG parameters

    Change of QTcF in ms

    Time frame: Day 1-28

  20. Effect of AP303 on ECG parameters

    Change of QTcB in ms

    Time frame: Day 1-28

  21. Vital signs(Systolic blood pressure)

    Change of systolic blood pressure

    Time frame: Day 1-28

  22. Effect of AP303 on physical examination result

    Number of pariticipants with abnormal physical examination findings by nature and severity

    Time frame: Day 1-28

  23. Body weight

    Change of body weight

    Time frame: Day 1-28

  24. Vital signs (Diastolic blood pressure)

    Change of diastolic blood pressure

    Time frame: Day1-28

  25. Vitlal signs (Body temperature)

    Change of body temperature

    Time frame: Day 1-28

  26. Effect of AP303 on ECG parameters

    Number of participants with abnormal QTcB.

    Time frame: Day 1-28

  27. Effect of AP303 on ECG parameters

    Number of participants with abnormal QTcF

    Time frame: Day 1-28

  28. Effect of AP303 on ECG parameters

    Number of participants with abnormal QRS

    Time frame: Day 1-28

  29. Effect of AP303 on ECG parameters

    Number of participants with abnormal PR

    Time frame: Day 1-28

  30. Effect of AP303 on ECG parameters

    Number of participants with abnormal QT

    Time frame: Day 1-28

  31. Effect of AP303 on ECG parameters

    Number of participants with abnormal heart rate

    Time frame: Day 1-28

Secondary outcomes

  1. Fasting glucose

    Change of fasting glucose

    Time frame: Baseline, Days 6, 10, 14 and 28

  2. Fasting lipid profile

    Change of Triglyceride, HDL-C, LDL-C, Total cholesterol

    Time frame: Baseline, Days 6, 10, 14 and 28

  3. Serum creatinine

    Change of serum creatinine

    Time frame: Baseline, Days 6, 10, 14 and 28

  4. eGFR

    Change of estimated glomerular filtration rate

    Time frame: Baseline, Days 6, 10, 14 and 28

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Sep 2025, 6 months after the start.

Of 20 phase 1 interventional studies under Diabetic Nephropathies, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 37. This study's planned 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2024
First posted
Oct 30, 2024
StartActual
Feb 27, 2025
Primary completionEst.
Sep 25, 2025
CompletionEst.
Sep 25, 2025
Last update
Sep 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06666283
Lead sponsor
Alebund Pharmaceuticals
Responsible party
Sponsor
First posted
Oct 30, 2024
Start date
Feb 27, 2025
Primary completion
Sep 25, 2025 (estimated)
Completion
Sep 25, 2025 (estimated)
Last update
Sep 11, 2025

Study contacts

Yuran Zhang
Contact
yuran.zhang@alebund.com
+8613661548603
Jue Huang
Contact
jue.huang@alebund.com
+8613764056397
Hong Zhang
principal investigator · Peking University First Hospital
Ying Gao
principal investigator · Peking University First Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AP303

Start the discussion